Goldman Sachs
OMED

Goldman Sachs’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Goldman Sachs’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-256,300
Closed -$2.36M – 7212
2017
Q1 		$2.36M Buy
+256,300
New +$2.25M ﹤0.01% 3583
2016
Q2 		– Sell
-50,000
Closed -$506K – 7566
2016
Q1 		$506K Buy
50,000
+600
+1% +$7.04K ﹤0.01% 4729
2015
Q4 		$1.11M Buy
49,400
+2,200
+5% +$45.1K ﹤0.01% 4191
2015
Q3 		$783K Buy
+47,200
New +$946K ﹤0.01% 4712

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs's OMED Position: Q4 2018 in Review

Goldman Sachs sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 24,200 shares — an estimated $51K sold.

Goldman Sachs first reported a position in OMED in Q3 2013 and held it in 16 quarters. The position peaked at $3.01M in Q1 2017. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Goldman Sachs reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Goldman Sachs sold 24,200 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $51K.
  • Goldman Sachs first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 16 quarters.
  • Goldman Sachs's OncoMed Pharmaceuticals, Inc. position peaked at $3.01M in Q1 2017.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.